Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments
Oral GLP-1, Injectable GGG Agonists Moving Into Phase III
Lilly will increase spending, resulting in lower-than-expected EPS, to drive its revenue growth, relying on sales of new products, particularly its next generation of incretin agonists for diabetes and obesity.
